|Day Low/High||2.22 / 2.32|
|52 Wk Low/High||1.92 / 5.47|
NewLink Genetics, Inovio Pharmaceuticals and Juno Therapeutics were among the biotech stock movers in premarket trading on Thursday.
FDA removes clinical hold on phase 3; Inovio to immediately begin recruiting subjects
Zika DNA vaccine may protect against sexual transmission
Phase 1b/2 clinical trial to evaluate combination of Inovio's T cell immunotherapy INO-5401 and Genentech's PD-L1 checkpoint inhibitor atezolizumab
Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.
Amongst highest levels of immune responses ever demonstrated in an HIV vaccine human study
Phase 1b/2a study combines MedImmune's MEDI0457 (INO-3112), a DNA-based immunotherapy targeting HPV-associated cancer, and durvalumab, an immune checkpoint (PD-L1) inhibitor
Horizon Pharma, OncoMed Pharmaceuticals and Inovio Pharmaceuticals were among the biotech stock movers in early trading on Monday.
Phase 1b/2a clinical trial will combine Regeneron's PD-1 inhibitor REGN2810 and Inovio's T cell activator INO-5401 and immune activator INO-9012 in brain cancer
The vaccine study showed that 95% of subjects generated an Ebola-specific antibody immune response.
Grant will fund therapeutic clinical studies testing PENNVAX-GP with INO-9012 (an IL-12 immune activator) alone and with the addition of a PD-1 checkpoint inhibitor
Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the November 17th expiration.
Former Novartis CFO brings finance, fundraising and M&A experience to Inovio
Seres Therapeutics, PTC Therapeutics and Inovio Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.
These heavily shorted stocks could get squeezed higher if they report positive earnings this week.
Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the April 21st expiration.
SynCon WT1 and PSMA antigens join hTERT in INO-5401, Inovio's cancer product planned for immuno-oncology combination study
These four biotech stocks have been moving on some interesting news and clinical results.
Other movers include Incyte, Achillion and Inovio.
Jim Cramer is bullish on Hershey, Nvidia, Accenture, Cheniere Energy. He's bearish on Emerge Energy and Seaspan.
Don't get upended by the rhetoric. The transports are confirming, banks are solid, there's a genuine uptick in commerce and earnings are strong, says Jim Cramer.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.